摘要
目的对舒肝解郁胶囊治疗抑郁症的系统评价(SR)/Meta分析(MA)进行再评价,以期为临床实践提供证据支持。方法计算机检索中国知识资源总库(CNKI)、万方数据知识服务平台(万方数据)、中文科技期刊数据库(维普网)、中国生物医学文献数据库(CBM)、PubMed、Web of Science、Cochrane Library数据库,并查询Clinical Trials.gov和中国临床试验注册中心两大临床试验注册系统,收集舒肝解郁胶囊治疗抑郁症的中英文文献,检索时间范围自建库至2022年2月。对最终纳入的SR/MA使用AMSTAR-2量表、PRISMA声明及GRADE系统分别进行方法学质量评价、报告质量评价和证据等级评价。结果共纳入11篇SR/MA,36个临床结局指标。AMSTAR-2评价结果显示,11篇SR/MA中1篇为低质量,其余10篇均为极低质量。PRISMA声明评价结果显示,9篇SR/MA报告质量评分15~20分,报告有一定缺陷;2篇SR/MA<15分,报告信息缺陷严重。GRADE系统对36个临床结局指标进行质量评价,结果为中级证据4个,其余为低级或极低级证据,4个中级证据中1个采用治愈率,2个采用有效率,1个采用不良反应。结论舒肝解郁胶囊治疗抑郁症疗效较好,不良反应少,但证据水平有待提高。舒肝解郁胶囊治疗抑郁症的有效性和安全性仍需更多高质量研究进一步验证,相关SR/MA制作应重视报告规范。
Objective To overview the systematic reviews(SR)/Meta-analysis(MA)of Shugan Jieyu Capsules in treatment of depression;To provide evidence support for clinical practice.Methods CNKI,Wanfang Data,VIP,CBM,PubMed,Web of Science,and Cochrane Library were retrieved and two major clinical trial registration systems:Clinical Trials.gov and China Clinical Trial Registration Center were searched to collect Chinese and English literature about Shugan Jieyu Capsules in treatment of depression.The retrieval time was from the establishment of the databases to the Feb.2022.AMSTAR-2 scale,PRISMA statement and GRADE system were used to evaluate the methodology quality,report quality and evidence level of the final included SR/MA.Results Totally 11 SR/MA were enrolled,with 36 clinical outcome indicators.The AMSTAR-2 evaluation results showed that one of the 11 SR/MA was of low quality,and the other 10 were of extremely low quality.The evaluation results of PRISMA statement showed that the reports of 9 SR/MA had certain defects with the scores of 15–20,and the other two reports had serious defects with the scores less than 15.GRADE system showed that 36 clinical outcome indicators were evaluated,4 of which were intermediate-level ones,and the rest were low-level or very low-level ones.One pieces of evidence of the 4 pieces of intermediate evidence were recovery rate,two pieces of intermediate evidence was efficiency,and one was with adverse reactions.Conclusion Shugan Jieyu Capsules are effective in the treatment of depression with fewer adverse reactions.However,the quality of evidence needs to be improved.The efficacy and safety of Shugan Jieyu Capsules in the treatment of depression still need to be further verified by more high-quality studies,and more attention should be paid to reporting standards in the preparation of SR/MA.
作者
马华萍
韩振蕴
胡文悦
常泽
王育纯
胡玉立
MA Huaping;HAN Zhenyun;HU Wenyue;CHANG Ze;WANG Yuchun;HU Yuli(Beijing University of Chinese Medicine,Beijing 100029,China;Shenzheng Hospital of Beijing University of Chinese Medicine(Longgang),Shenzhen 518100,China)
出处
《中国中医药信息杂志》
CAS
CSCD
2023年第2期39-46,共8页
Chinese Journal of Information on Traditional Chinese Medicine
基金
国家重点研发计划(2019YFC1710103)。
